Recombinant Human/Mouse/Rat TGFB3 Protein

Name: Recombinant Human/Mouse/Rat TGFB3 Protein
Brand: Beta LifeScience
SKU: BL-1739NP
Price: 368.0 USD
Availability: InStock

BL-1739NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Collections: Cytokines, Cytokines and growth factors, Growth factors and receptors, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human/Mouse/Rat Transforming Growth Factor Beta 3 is produced by our Mammalian expression system and the target gene encoding Ala301-Ser412(Tyr340Phe) is expressed.
Accession	P10600
Synonym	Transforming growth factor beta-3; TGFB3; TGF-beta-3; Latency-associated peptide; LAP
Gene Background	Transforming growth factor beta 3(TGFB3) is a member of a TGF -β superfamily which is defined by theirstructural and functional similarities. TGFB3 is secreted as a complex with LAP. This latent form of TGFB3becomes active upon cleavage by plasmin, matrix metalloproteases, thrombospondin -1, and a subset ofintegrins. It binds with high affinity to TGF- β RII, a type II serine/threonine kinase receptor. TGFB3 is involved incell differentiation, embryogenesis and development.It is believed to regulate molecules involved in cellularadhesion and extracellular matrix (ECM) formation during the process of palate development. Without TGF-β3,mammals develop a deformity known as a cleft palate.
Molecular Mass	12.7 KDa
Apmol Mass	12-14 KDa, reducing conditions
Formulation	Lyophilized from a 0.2 μm filtered solution of 50mM Glycine-HCl, 150mM NaCl, pH 2.5.
Endotoxin	Less than 0.001 ng/µg (0.01 EU/µg) as determined by LAL test.
Purity	Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity	Biologically active. Please contact us to obtain bioactivity data.
Reconstitution	Always centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping	The product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.
Usage	For Research Use Only

Target Details

Target Function	Transforming growth factor beta-3 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-3 (TGF-beta-3) chains, which constitute the regulatory and active subunit of TGF-beta-3, respectively.; Required to maintain the Transforming growth factor beta-3 (TGF-beta-3) chain in a latent state during storage in extracellular matrix. Associates non-covalently with TGF-beta-3 and regulates its activation via interaction with 'milieu molecules', such as LTBP1 and LRRC32/GARP, that control activation of TGF-beta-3. Interaction with integrins results in distortion of the Latency-associated peptide chain and subsequent release of the active TGF-beta-3.; Transforming growth factor beta-3: Multifunctional protein that regulates embryogenesis and cell differentiation and is required in various processes such as secondary palate development. Activation into mature form follows different steps: following cleavage of the proprotein in the Golgi apparatus, Latency-associated peptide (LAP) and Transforming growth factor beta-3 (TGF-beta-3) chains remain non-covalently linked rendering TGF-beta-3 inactive during storage in extracellular matrix. At the same time, LAP chain interacts with 'milieu molecules', such as LTBP1 and LRRC32/GARP that control activation of TGF-beta-3 and maintain it in a latent state during storage in extracellular milieus. TGF-beta-3 is released from LAP by integrins: integrin-binding results in distortion of the LAP chain and subsequent release of the active TGF-beta-3. Once activated following release of LAP, TGF-beta-3 acts by binding to TGF-beta receptors (TGFBR1 and TGFBR2), which transduce signal.
Subcellular Location	[Latency-associated peptide]: Secreted, extracellular space, extracellular matrix.; [Transforming growth factor beta-3]: Secreted.
Protein Families	TGF-beta family
Database References	HGNC: 11769 OMIM: 107970 KEGG: hsa:7043 STRING: 9606.ENSP00000238682 UniGene: Hs.592317
Associated Diseases	Arrhythmogenic right ventricular dysplasia, familial, 1 (ARVD1); Loeys-Dietz syndrome 5 (LDS5)

Gene Functions References

Elevations of TGF-beta3, SMAD2 and SMAD4 in hypertrophic scars and increase of IGF-1R in immature stages may give some clues for acne hypertrophic scar formation. PMID: 30167815
This review highlights advances in the understanding of the cellular sources, activation processes, contextual determinants, and immunological roles of TGF-beta3 with comparisons to other TGF-beta isoforms. PMID: 30071700
This study showed that YOD1 overexpression enhances cell migration by promoting TGF-beta3 signaling which may play an important role in lip and palate formation. PMID: 30145984
We suggest that increased TGFbeta3 levels are responsible for development of aggressive prostate cancer in African American patients as a consequence of development of resistance to inhibitory effects of TGFbeta on cell proliferation and induction of invasive metastatic behavior PMID: 29474521
data implies that miR-140 is a potent chondrogenic differentiation inducer for iPSCs and also, we have showed increasing chondrogenic differentiation by using overexpression of miR-140 and TGFbeta3. PMID: 29456027
The increase in TGF-beta3 found in inflammatory wound healing (WF) highlights its negative effect on wound healing, while the increased levels of sEng in granulating WF affects the leukocyte adhesion/transmigration through the endothelium, reducing the inflammatory response and favoring the wound healing. PMID: 29065449
In nonsyndromic CL+/-P Malay patients,the prevalence of the mutations in the TGFbeta3 gene was 17.7%. For the TGFbeta3 gene, there was no mutation in the coding region in either of the groups. PMID: 26151095
Human dental apical papilla-derived Mesenchymal stem cells (hSCAPs) can produce and secrete TGFbeta3 in response to micro-environmental cues. PMID: 25690385
Higher TGF-beta3 serum concentrations are a risk factor for uterine fibroids. PMID: 27743697
High expression of TGF-beta3 in preeclampsia decidua stimulates miR-494 in decidual mesenchymal stem cells (MSC) and attenuates the regulation of MSC switching the macrophage toward M2 type, contributing to an immune imbalance at maternal-fetal interface. PMID: 27149081
The frequency GA genotype of transforming growth factor beta 3 (TGFbeta3) gene was associated with increased risk of non-syndromic cleft palate only (NS CPO). PMID: 28364787
combining TGF-beta3 with BMP-2 was able to promote the process of bone formation more markedly in vitro, providing a promising clinical strategy in the field of skeletal regeneration and in fracture healing. PMID: 27878265
No significant association was observed in MMP13, TIMP2 and TGFB3 genes with CP or PI. CP is a risk factor to develop PI, however, there is no association of both diseases with polymorphisms in the MMP13, TIMP2 and TGFB3 genes PMID: 27058373
Our study showed that TGFA/TGFB3/MSX1 gene polymorphisms were associated with congenital NSHI. CCGTAC and TTACGT haplotypes might be protective factors, while TTGCGC haplotype might be a risk factor for congenital NSHI. TGFA/TGFB3/MSX1 gene rs3771494, rs1058213, rs3917201, rs2268626, rs3821949, and rs62636562 haplotype analysis showed that haplotype CCGTAC and TTACGT might be protective factors (both P<0.001) PMID: 27356075
increased stromal POSTN induced by TGF-beta3 directly accelerated the growth, migration and invasion of cancer cells PMID: 26857387
Taken together, these results demonstrate that insulin and TGF-beta3 present antagonistic effects during the chondrogenesis of human bone marrow-derived stem/progenitor cells. PMID: 26866713
CCN4 has a positive influence on chondrogenic differentiation by modulating the effects of TGF-beta3. PMID: 26555637
TGFB3 polymorphism is associated with male infertility. PMID: 26612435
Results identified a novel human TGFB3 mutation, which contributes to the clinical delineation of the emerging connective tissue disorder tentatively called Rienhoff syndrome, a disorder overlapping with Marfan and Loeys-Dietz syndrome. PMID: 26184463
Fluocinolone Acetonide enhances TGF-beta3-associated chondrogenesis of bone marrow derived mesenchymal stem cells PMID: 25753754
TGF-beta3-expressing CD4+CD25(-)LAG3+ regulatory T cells have a role in controlling humoral immune responses PMID: 25695838
TGF-beta3 mediates the attenuating effect of MSCs on both the proliferation and extracellular matrix production of human keloid fibroblasts and decreases skin fibrosis PMID: 25858630
TGF-beta3 existed in synovium and LBs of SC, and was responsible for the pathogenesis of SC. PMID: 25742744
TGFB3 polymorphism, significant differences were observed for allele and genotype frequencies between caries free and caries affected individuals in oral cleft group (p = 0.013 and 0.006 for allele and genotype frequencies respectively). PMID: 25307808
TGF-beta3 may contribute to the persistent intestinal dysfunction seen in gastroschisis-related intestinal dysfunction. PMID: 25431043
Data indicate greater staining for transforming growth factor beta 3 (TGF-beta3) in healthier tissue compared with diseased menisci. PMID: 25418724
The results show an intricate interplay between p53 and TGF-beta3 whereby p53 inhibits the TGF-beta3-induced expression of genes, e.g., EPHB2, to impede tumor cell invasion and migration PMID: 25257729
findings emphasize the broad clinical variability associated with TGFB3 mutations and highlight the importance of early recognition of the disease because of high cardiovascular risk PMID: 25835445
It was found that the majority of TGF-beta3 that was loaded onto the scaffold was released in a controlled manner over the first 10days of culture, with comparable long-term chondrogenesis PMID: 24907658
We identified genetic variants in TGFB3 and ARHGAP29 associated with suboptimal healing outcome. PMID: 24635173
These results unequivocally demonstrate that human TGF-beta3 elicits bone induction by up-regulation of endogenous BMP-2 and is blocked by hNoggin. PMID: 24438909
TGF-beta3 could be stably expressed in pcDNA3.1(+)-hTGF-beta3-transfected PSCs. PMID: 21823016
Liarozole decreased TGF-beta3 and TGF-beta3-mediated extracellular matrix expression in a 3D uterine leiomyoma culture system. PMID: 24825427
meta-analysis suggests that TGF-beta3 gene polymorphisms may contribute to NSCLP susceptibility, especially among Asian populations. PMID: 24053560
Allelic and haplotypic associations implicate a possible role of TGFB3 in nonsyndromic cleft lip with or without cleft palate in the Chilean population. PMID: 20170386
This study provides a comprehensive list of genes differentially expressed in the healing corneal epithelial cells of diabetic corneas and suggests the therapeutic potential of TGF-beta3 for treating corneal and skin wounds in diabetic patients. PMID: 24306208
The GG genotype and G allele of TGF-beta 3 were significantly different in the patient group compared with the control. PMID: 23023602
Shear stress of vascular endothelial cells induces TGF-beta3 signaling and subsequent activation of Kruppel-like factor 2 and NO, and represents a novel role for TGF-beta3 in the maintenance of homeostasis in a hemodynamic environment. PMID: 23968981
Mutation in TGFB3 is associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome. PMID: 23824657
These findings suggest human serum, FGF-2 and TGF-beta3 as possible candidates to support biological treatment strategies of AF defects. PMID: 23122986
These results highlight TGFbeta/5-HT signaling as a potent mechanism for control of biomechanical remodeling of atrioventricular cushions during development. PMID: 22880017
Hypoxia may inhibit the invasion of human extravillous trophoblast cells through inducing the integrin switch from alpha1 integrin to alpha5 integrin and promoting TGFB3 expression. PMID: 22674391
IL-1B & TGFB3 synergistically activated MMP)-1, MMP-3,& MMP-10 gene expression in NSCLC cells via MAPK-dependent pathways. PMID: 22796605
Significant statistical differences were found for genotype frequencies between tooth agenesis and TGFB3 control samples, as well as for allele and genotype frequencies between unilateral tooth agenesis and TGFB3 control samples. PMID: 22191848
TGF-beta3 isoform is a key agent in seminal plasma that signals induction of proinflammatory cytokine synthesis in cervical cells. PMID: 22706080
analysis of genetic variants hints at the contribution of TGFB3 and MN1 in the aetiology of submucous cleft palate PMID: 22409215
involved in the modulation of epithelial barrier function by regulating assembly of tight junctions PMID: 22369552
This study confirms the crucial role of TGF-beta3 in the fusion of palatal shelves during development and further, provides novel evidence of TGF-beta3 gene polymorphism in the etiology of nonsyndromic cleft lip and palate in Indian subpopulation PMID: 22143699
We observed significant downregulation of Transforming Growth Factor beta 3 in women with recurrent miscarriage compared with controls. PMID: 22266274
study suggests that both combination medium, but better with the addition of TGF-ss3 could enhance BMSCs chondrogenesis in vivo, and promotes themaintenance of the chondrocyte phenotype PMID: 21666950

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.